Thomas P. Schnettler - 21 May 2021 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: Director
Signature: /s/ Thomas P. Schnettler, by Joseph Driscol, as Attorney-in-Fact
Issuer symbol: AKYA
Transactions as of: 21 May 2021
Net transactions value: $0
Form type: 4
Filing time: 25 May 2021, 21:55:33 UTC
Next filing: 14 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AKYA	Common Stock						2,813,771	21 May 2021	Held by Piper Sandler Merchant Banking Fund II, L.P.	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKYA	Stock Option (Right to Buy	Award	$0	+16,860		$0.000000	16,860	21 May 2021	Common Stock	16,860	$21.95	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	PSC Capital Management II LLC is the general partner of Piper Sandler Merchant Banking Fund II, L.P. Piper Sandler Companies is the manager of PSC Capital Management II LLC. The reporting person is the Co-CEO of PSC Capital Management II LLC and disclaims beneficial ownership of the shares held by Piper Sandler Merchant Banking Fund II, L.P.
F2	Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) May 21, 2022, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.